Male patients between 40 and 75 years old with low- or intermediate-grade prostate cancer have a PSA level <20 ng/ml and have chosen radical prostatectomy, brachytherapy, or active surveillance as their main treatment. This evidence concerns the gene KLK3 and prostate cancer.